| CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD … ES Antonarakis, P Isaacsson Velho, W Fu, H Wang, N Agarwal, ... JCO precision oncology 4, 370-381, 2020 | 181 | 2020 |
| Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations ES Antonarakis, F Shaukat, PI Velho, H Kaur, E Shenderov, DM Pardoll, ... European urology 75 (3), 378-382, 2019 | 175 | 2019 |
| Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer P Isaacsson Velho, JL Silberstein, MC Markowski, J Luo, TL Lotan, ... The Prostate 78 (5), 401-407, 2018 | 123 | 2018 |
| PD-1/PD-L1 pathway inhibitors in advanced prostate cancer P Isaacsson Velho, ES Antonarakis Expert review of clinical pharmacology 11 (5), 475-486, 2018 | 105 | 2018 |
| Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects PI Velho, F Qazi, S Hassan, MA Carducci, SR Denmeade, MC Markowski, ... European urology 76 (2), 170-176, 2019 | 85 | 2019 |
| Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, MA Bilen, V Santos, J Esther, ... Cancer 126 (6), 1208-1216, 2020 | 80 | 2020 |
| The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited MP Deek, K Van der Eecken, R Phillips, NR Parikh, PI Velho, TL Lotan, ... European urology 80 (5), 632-640, 2021 | 78 | 2021 |
| Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer PI Velho, W Fu, H Wang, N Mirkheshti, F Qazi, FAS Lima, F Shaukat, ... European urology 77 (1), 14-21, 2020 | 76 | 2020 |
| Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer U Swami, PI Velho, R Nussenzveig, J Chipman, VS Santos, S Erickson, ... European urology 78 (5), 652-656, 2020 | 68 | 2020 |
| Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer MP Deek, K Taparra, R Phillips, PI Velho, RW Gao, C Deville, DY Song, ... European urology oncology 4 (3), 447-455, 2021 | 62 | 2021 |
| Targeting the PI3K pathway in head and neck squamous cell carcinoma PH Isaacsson Velho, G Castro Jr, CH Chung American Society of Clinical Oncology Educational Book 35 (1), 123-128, 2015 | 54 | 2015 |
| Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer MJ van der Doelen, PI Velho, PHJ Slootbeek, SP Naga, M Bormann, ... European Journal of Cancer 136, 16-24, 2020 | 48 | 2020 |
| A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, NJ Miller, L Carril-Ajuria, ... European urology oncology 4 (3), 464-472, 2021 | 46 | 2021 |
| Pulmonary nodules in patients with Nonpulmonary cancer: not always metastases R Caparica, MP Mak, CH Rocha, PHI Velho, P Viana, MRL Moura, ... Journal of global oncology 2 (3), 138-144, 2016 | 45 | 2016 |
| Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair‐deficient prostate cancer LA Sena, J Fountain, P Isaacsson Velho, SJ Lim, H Wang, E Nizialek, ... The Oncologist 26 (2), e270-e278, 2021 | 42 | 2021 |
| Histological subtypes and response to PD-1/PD-L1 blockade in advanced urothelial cancer: a retrospective study NJ Miller, AR Khaki, LN Diamantopoulos, MA Bilen, V Santos, N Agarwal, ... The Journal of urology 204 (1), 63-70, 2020 | 39 | 2020 |
| Clinical and genomic features of SPOP‐mutant prostate cancer M Nakazawa, M Fang, C H. Marshall, TL Lotan, P Isaacsson Velho, ... The Prostate 82 (2), 260-268, 2022 | 26 | 2022 |
| Molecular characterization and clinical outcomes of primary Gleason pattern 5 prostate cancer after radical prostatectomy P Isaacsson Velho, D Lim, H Wang, JC Park, HB Kaur, F Almutairi, ... JCO precision oncology 3, 1-13, 2019 | 24 | 2019 |
| Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes SM Esagian, AR Khaki, LN Diamantopoulos, L Carril‐Ajuria, D Castellano, ... BJU international 128 (2), 196-205, 2021 | 22 | 2021 |
| Genomic and clinical characterization of pulmonary‐only metastatic prostate cancer: A unique molecular subtype E Shenderov, P Isaacsson Velho, AH Awan, H Wang, N Mirkheshti, ... The Prostate 79 (13), 1572-1579, 2019 | 22 | 2019 |
